Sanofi (SNY) Receives Consensus Rating of “Hold” from Brokerages
Sanofi (NYSE:SNY) has been given a consensus rating of “Hold” by the seventeen research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $54.00.
Several research analysts recently commented on the company. BidaskClub upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research note on Friday, June 2nd. HSBC Holdings plc upgraded Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. Argus reiterated a “buy” rating and issued a $55.00 price target on shares of Sanofi in a research note on Friday, September 1st. Finally, Cowen and Company reiterated a “market perform” rating and issued a $52.00 price target (up previously from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st.
ILLEGAL ACTIVITY WARNING: “Sanofi (SNY) Receives Consensus Rating of “Hold” from Brokerages” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://theolympiareport.com/2017/09/09/sanofi-sny-receives-consensus-rating-of-hold-from-brokerages.html.
Sanofi (SNY) traded up 0.10% on Friday, hitting $49.37. The stock had a trading volume of 1,313,875 shares. The firm has a market cap of $123.99 billion, a PE ratio of 11.76 and a beta of 0.88. The company’s 50 day moving average is $48.20 and its 200 day moving average is $47.11. Sanofi has a 12-month low of $36.81 and a 12-month high of $50.24.
Sanofi (NYSE:SNY) last released its quarterly earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The business had revenue of $8.66 billion for the quarter, compared to analysts’ expectations of $8.71 billion. The business’s revenue for the quarter was down 2.3% on a year-over-year basis. On average, equities research analysts expect that Sanofi will post $3.34 EPS for the current fiscal year.
In other news, major shareholder Sanofi acquired 60,595 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The stock was purchased at an average cost of $478.98 per share, with a total value of $29,023,793.10. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.00% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the company. Harbour Capital Advisors LLC bought a new position in shares of Sanofi during the first quarter valued at approximately $113,000. Parallel Advisors LLC grew its holdings in shares of Sanofi by 42.5% during the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after purchasing an additional 875 shares during the last quarter. YorkBridge Wealth Partners LLC grew its holdings in shares of Sanofi by 33.7% during the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after purchasing an additional 776 shares during the last quarter. Bronfman E.L. Rothschild L.P. grew its holdings in shares of Sanofi by 142.8% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after purchasing an additional 2,098 shares during the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC grew its holdings in shares of Sanofi by 6,188.3% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock valued at $171,000 after purchasing an additional 3,713 shares during the last quarter. 9.33% of the stock is owned by institutional investors.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.